<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838252</url>
  </required_header>
  <id_info>
    <org_study_id>12-001629</org_study_id>
    <nct_id>NCT01838252</nct_id>
  </id_info>
  <brief_title>Hyaluronic Acid Gels for Lower Lid Retraction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lid retraction is a difficult problem encountered in oculofacial plastic surgery. It can&#xD;
      result from previous surgery, radiotherapy or cicatrizing disease or it may be idiopathic.&#xD;
      Whatever the aetiology, the cosmetic appearance is troublesome to patients and, can be&#xD;
      damaging to the cornea. The definitive therapy for lid retraction is surgical, and often&#xD;
      involves complicated procedures including tissue grafting.&#xD;
&#xD;
      Hyaluronic acid gels (HAG) have been FDA approved for the treatment of facial rhytids by&#xD;
      subcutaneous injection and volume addition. These gels have gained wide popularity in for&#xD;
      cosmetic applications in filling volume deficit areas. Functional applications in the&#xD;
      periorbital area have also been described including the filling of volume deficit&#xD;
      anophthalmic orbits, ectropion and loagophthalmos. Additionally, pilot studies have found HAG&#xD;
      to be useful in correcting both upper and lower eyelid retraction, with good effect.&#xD;
&#xD;
      The purpose of this investigation is to define the clinical utility of HAG correction of&#xD;
      lower eyelid retraction in terms of anatomic (lid position), quantitative (dry eye signs on&#xD;
      cornea) and qualitative effects (symptom severity).&#xD;
&#xD;
      Our hypothesis is that HAG correction of lower eyelid retraction will improve patient&#xD;
      comfort, clinical signs of dry eye and aesthetic self image.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower eyelid position</measure>
    <time_frame>6 weeks</time_frame>
    <description>Decrease in inferior scleral show</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective dry eye symptoms</measure>
    <time_frame>6 weeks</time_frame>
    <description>Ocular surface disease index score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective dry eye signs</measure>
    <time_frame>6 weeks</time_frame>
    <description>NEI dry eye score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective dry eye signs</measure>
    <time_frame>6 weeks</time_frame>
    <description>Oxford staining score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ectropion</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive hyaluronic acid fillers to the lower lid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position</description>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <other_name>Restylane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline will be injected in to the lower lid, elevating it to a more anatomic position</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Lower eyelid retraction of &gt;1mm in one or both eyes.&#xD;
&#xD;
          2. Complaints of either significant ocular symptoms (OSDI&gt;13) or cosmetic deformity&#xD;
             associated with the eyelid retraction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 21 years: due to lack of data on safety for HAG fillers in pediatric&#xD;
             population&#xD;
&#xD;
          2. Age over 65 years of age: as HAG filler effect may be different in this population&#xD;
&#xD;
          3. Are pregnant or nursing: as there is little safety data on potential teratogenicity of&#xD;
             HAG fillers&#xD;
&#xD;
          4. Have a demonstrated allergy to HAG fillers or lidocaine&#xD;
&#xD;
          5. Have a current infection, skin sore, pimple, rash, hive or cyst over the injection&#xD;
             site: to avoid worsening the infection or transmitting it&#xD;
&#xD;
          6. Have a bleeding disorder or currently taking blood-thinning medications such as&#xD;
             Coumadin or heparin on a daily basis.&#xD;
&#xD;
          7. Currently active stage Thyroid Eye Disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B Rootman, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Daniel Rootman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Ectropion</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <keyword>Lower eyelid retraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ectropion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

